WARNING: This product is for research use only, not for human or veterinary use.
MedKoo CAT#: 406719
Description: TBCA, also known as tetrabromocinnamic acid, is a potent CK2 inhibitor. TBCA inhibits CK2 five times more efficiently than TBB (IC50 values 0.11 and 0.56 microM, respectively), without having any comparable effect on DYRK1 a (IC50 24.5 microM) or on a panel of 28 protein kinases. The usefulness of TBCA for cellular studies has been validated by showing that it reduces the viability of Jurkat cells more efficiently than TBB through enhancement of apoptosis.
MedKoo Cat#: 406719
Chemical Formula: C9H4Br4O2
Exact Mass: 459.69448
Molecular Weight: 463.74286
Elemental Analysis: C, 23.31; H, 0.87; Br, 68.92; O, 6.90
TBCA is not in stock, but may be available through custom synthesis. For cost-effective reason, minimum 1 gram order is requested. The product will be characterized by NMR, HPLC and MS analysis. Purity (HPLC) is usually >98%. CoA, QC data, MSDS will be provided when product is successfully made. The estimated lead time is 2-3 months. Please send email to email@example.com to inquire quote.
Synonym: TBCA, tetrabromocinnamic acid
IUPAC/Chemical Name: (E)-3-(2,3,4,5-tetrabromophenyl)acrylic acid
InChi Key: SVJQCVOKYJWUBC-OWOJBTEDSA-N
InChi Code: InChI=1S/C9H4Br4O2/c10-5-3-4(1-2-6(14)15)7(11)9(13)8(5)12/h1-3H,(H,14,15)/b2-1+
SMILES Code: O=C(O)/C=C/C1=CC(Br)=C(Br)C(Br)=C1Br
The following data is based on the product molecular weight 463.74286 Batch specific molecular weights may vary from batch to batch due to the degree of hydration, which will affect the solvent volumes required to prepare stock solutions.
|Concentration / Solvent Volume / Mass||1 mg||5 mg||10 mg|
|1 mM||1.15 mL||5.76 mL||11.51 mL|
|5 mM||0.23 mL||1.15 mL||2.3 mL|
|10 mM||0.12 mL||0.58 mL||1.15 mL|
|50 mM||0.02 mL||0.12 mL||0.23 mL|
1: Lee HR, Shin HK, Park SY, Kim HY, Lee WS, Rhim BY, Hong KW, Kim CD. Attenuation of β-amyloid-induced tauopathy via activation of CK2α/SIRT1: Targeting for cilostazol. J Neurosci Res. 2014 Feb;92(2):206-17. doi: 10.1002/jnr.23310. Epub 2013 Nov 19. PubMed PMID: 24254769.
2: Ryu SY, Kim S. Evaluation of CK2 inhibitor (E)-3-(2,3,4,5-tetrabromophenyl)acrylic acid (TBCA) in regulation of platelet function. Eur J Pharmacol. 2013 Nov 15;720(1-3):391-400. doi: 10.1016/j.ejphar.2013.09.064. Epub 2013 Oct 15. PubMed PMID: 24140231.
3: Lee HR, Park SY, Kim HY, Shin HK, Lee WS, Rhim BY, Hong KW, Kim CD. Protection by cilostazol against amyloid-β(1-40)-induced suppression of viability and neurite elongation through activation of CK2α in HT22 mouse hippocampal cells. J Neurosci Res. 2012 Aug;90(8):1566-76. doi: 10.1002/jnr.23037. Epub 2012 Mar 16. PubMed PMID: 22422579.
4: Yao K, Youn H, Gao X, Huang B, Zhou F, Li B, Han H. Casein kinase 2 inhibition attenuates androgen receptor function and cell proliferation in prostate cancer cells. Prostate. 2012 Sep 15;72(13):1423-30. doi: 10.1002/pros.22493. Epub 2012 Jan 30. PubMed PMID: 22290244.
5: Kim GS, Jung JE, Narasimhan P, Sakata H, Yoshioka H, Song YS, Okami N, Chan PH. Release of mitochondrial apoptogenic factors and cell death are mediated by CK2 and NADPH oxidase. J Cereb Blood Flow Metab. 2012 Apr;32(4):720-30. doi: 10.1038/jcbfm.2011.176. Epub 2011 Dec 7. PubMed PMID: 22146192; PubMed Central PMCID: PMC3318149.
6: Kramerov AA, Golub AG, Bdzhola VG, Yarmoluk SM, Ahmed K, Bretner M, Ljubimov AV. Treatment of cultured human astrocytes and vascular endothelial cells with protein kinase CK2 inhibitors induces early changes in cell shape and cytoskeleton. Mol Cell Biochem. 2011 Mar;349(1-2):125-37. doi: 10.1007/s11010-010-0667-3. Epub 2010 Dec 2. PubMed PMID: 21125314; PubMed Central PMCID: PMC3426611.
7: Pagano MA, Poletto G, Di Maira G, Cozza G, Ruzzene M, Sarno S, Bain J, Elliott M, Moro S, Zagotto G, Meggio F, Pinna LA. Tetrabromocinnamic acid (TBCA) and related compounds represent a new class of specific protein kinase CK2 inhibitors. Chembiochem. 2007 Jan 2;8(1):129-39. PubMed PMID: 17133643.